Category Archives: MSK in the News

Selected by library staff

MSKCC in the News: February 9 – February 23

Posted on by

 

  • ScienceInsider reported on a petition drafted by Robert Benezra at MSKCC that urges NIH to reconsider grant application rules that limits the number of times an applicant can submit a revised version of a grant application only once instead of twice.
  • Pharmaceutical Business Review recently announced a Phase 2 clinical trial sponsored by The Ludwig Institute for Cancer Research (LICR) evaluating the effectiveness of ADI-PEG 20 in the treatment of small cell lung cancer (SCLC) that will take place at MSKCC and Duke University Medical Center.
  • Dr. Scher of MSKCC announced at the fourth annual Genitourinary Cancers Symposium that an investigational drug called abiraterone acetate may help men with hard to treat prostate cancer.

    • MSKCC in the News: January 26 – February 9

    Posted on by
    • Dr. Monica Morrow of MSKCC was quoted in a New York Times article regarding a study she coauthored, which was recently published in The Journal of the American Medical Association, that revealed that removing cancerous lymph nodes proved unnecessary for many women with early breast cancer who had undergone chemotherapy and radiation.
    • Charles Sawyers, a cancer expert and Howard Hughes Medical Institute Investigator at MSKCC, in a Wall Street Journal article responded to recent findings that have identified a combination of four genes that appear to play a critical role in determining whether prostate cancer in its early stages will go on to become an aggressive, lethal disease.
    • MESOTHELIOMAhelp.net announced a collaboration between MSKCC and Agenus to test a cancer vaccine that is meant to activate and expand the “army” of T-cells, known to be responsible for killing tumor cells, and inhibit the agent that blocks T-cell signals from effectively killing the tumor.

    MSKCC in the News: January 12 – January 26

    Posted on by
    • Pnina Peled, the executive chef at MSKCC, was recently featured in a New York Times article.
    • Agenus Inc. recently announced it has entered into a research agreement with MSKCC to test Agenus’ cancer vaccine in combination with antibodies that are intended to target specific markers on tumor cells, such as CTLA-4 and PDL-1.
    • Dr. Paul Chapman, who led a trial for an experimental drug aimed at melanoma, was recently quoted in a New York Times article about the trial’s promising results.